We are pioneering a portfolio of RAS(ON) inhibitors using our revolutionary tri-complex inhibitor platform, which enables unprecedented access to the active form of oncogenic RAS and a differentiated approach to targeting what was historically one of the most notoriously undruggable targets in cancer.

Revolution Medicines is building a deep pipeline to enable the discovery, development and delivery of targeted therapies for patients in need of new therapeutic options. With our first wave of investigational RAS(ON) inhibitors – daraxonrasib (RMC-6236), a (RAS)ON multi-selective inhibitor, elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor, and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor – in the clinic, and a robust pre-clinical pipeline targeting a spectrum of additional RAS cancer mutations, we are on target to outsmart RAS-addicted cancers. Our pipeline is designed to offer the opportunity for our compounds to be evaluated as monotherapy and in combination with current standards of care and/or intra-pipeline agents.